Pemphigus;Pénfigo

Actas Dermo-Sifiliograficas

Volumn 96, Issue 6, 2005, Pages 329-356

  Sánchez Pérez, Javier ^a   García Díez, Amaro ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Clinical symptoms; Desmocollin 1; Desmoglein 1; Desmoglein 3; Diagnosis; ELISA; Etiology; Immunoblot; Immunoprecipitation; Pathogenesis; Pemphigus

Indexed keywords

DESMOCOLLIN; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN A; STEROID;

ACANTHOLYSIS; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPETIFORM PEMPHIGUS; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IMMUNOGLOBULIN A PEMPHIGUS; IMMUNOPRECIPITATION; MORBIDITY; MORTALITY; PARANEOPLASTIC PEMPHIGUS; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 24144451165     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-7310(05)73090-8     Document Type: Review

References (241)

1. King F, Holubar K. History of pemphigus. Clin Dermatol. 1983;1:6-12.
2. Holubar K. Historical background. En: Wojnarowska F, Briggaman RA, editors. Management of blistering diseases. Londres: Chapman and Hall Medical; 1990. p. 1-12.
3. Jablonska S, Chorzelski T, Beutner E, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 1975;14:353-9.
4. Ishii K, Amagai M, Komai A, et al. Desmoglein 1 and desmoglein 3 are the target autoantigens in herpetiform pemphigus. Arch Dermatol. 1999;135:943-7.
5. Wallach D, Foldes C, Cottenot F. Subcorneal pustulosis, superficial acantholysis and monoclonal IgA. Ann Dermatol Venereol. 1982;109:959-63.
6. Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol. 1999;40:649-71.
7. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729-35.
8. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol. 1997;12:77-96.
9. Hahn-Ristic K, Rzany B, Amagai M, Brocker EB, Zillikens D. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. JEADV. 2002;16:68-71.
10. Tsankov N, Vassileva S, Kamarashev J, Kazandjieva J, Kuzeva V. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980-1995). Int J Dermatol. 2000;39:104-8.
11. Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995;104:302-5.
12. Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol. 1992;31:42-5.
13. Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol. 1982;62:491-6.
14. Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980;116:1035-7.
15. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974;38:382-7.
16. Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995;104:302-5.
17. Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France. Incidence of foliaceus pemphigus in young Tunisian women. Ann Dermatol Venereol. 1996;123:337-42.
18. Aboobaker J, Morar N, Ramdial PK, Hammond MG. Pemphigus in South Africa. Int J Dermatol. 2001;40:115-9.
19. Aoki V, Millikan RC, Rivitti EA, et al. Cooperative Group for Fogo Selvagem Research. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc. 2004;9:34-40.
20. Arteaga LA, Rivitti EA, Aoki V, et al. The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J Invest Dermatol. 2003;120:104-8.
21. Abreu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 2003;49:599-608.
22. Morini JP, Jomaa B, Gorgi Y, et al. Pemphigus foliaceus in young women. An endemic focus in the Sousse area of Tunisia. Arch Dermatol. 1993;129:69-73.
23. Bastuji-Garin S, Turki H, Mokhtar I, et al. Possible relation of Tunisian pemphigus with traditional cosmetics: a multicenter case-control study. Am J Epidemiol. 2002;155: 249-56.
24. Kitajima Y. Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus. Arch Dermatol Res. 2003;295 (Suppl 1):17-23.
25. Ahmed AR, Mohimen A, Yunis EJ, et al. Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med. 1993;177:419-24.
26. Sinha AA, Brautbar C, Szafer F, et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science. 1988;239:1026-9.
27. Scharf SJ, Freidmann A, Steinman L, Brautbar C, Erlich HA. Specific HLA-DQB and HLA-DRB1 alleles confer susceptibility to pemphigus vulgaris. Proc Natl Acad Sci U S A. 1989;86:6215-9.
28. Wucherpfennig KW, Yu B, Bhol K, et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci U S A. 1995;92:11935-9.
29. Loiseau P, Lecleach L, Prost C, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun. 2000;15:67-73.
30. Miyagawa S, Niizeki H, Yamashina Y, Kaneshige T. Genotyping for HLA-A, B and C alleles in Japanese patients with pemphigus: prevalence of Asian alleles of the HLA-B15 - family. Br J Dermatol. 2002;146:52-8.
31. Slomov E, Loewenthal R, Goldberg I, Korostishevsky M, Brenner S, Gazit E. Pemphigus vulgaris in Jewish patients is associated with HLA-A region genes, mapping by microsatellite markers. Hum Immunol. 2003;64:771-9.
32. Gazit E, Loewenthal R. The immunogenetics of pemphigus vulgaris. Autoimmun Rev. 2005;4:16-20.
33. Brenner S, Bialy-Golan A, Ruocco V. Drug-induce pemphigus. Clin Dermatol. 1998;16:393-7.
34. Piontek JO, Borberg H, Sollberg S, Krieg T, Hunzelmann N. Severe exacerbation of pemphigus vulgaris in pregnancy: successful treatment with plasma exchange. Br J Dermatol. 2000;143:455-6.
35. Kalayciyan A, Engin B, Serdaroglu S, Mat C, Aydemir EH, Kotogyan A. A retrospective analysis of patients with pemphigus vulgaris associated with pregnancy. Br J Dermatol. 2002;147:396-7.
36. Reis VM, Toledo RP, López A, Díaz LA, Martins JE. UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J Am Acad Dermatol. 2000;42:571-6.
37. Cram DL, Winkelmann RK. Ultraviolet-induced acantholysis in pemphigus. Arch Dermatol. 1965;92:7-13
38. Muramatsu T, Iida T, Ko T, Shirai T. Pemphigus vulgaris exacerbated by exposure to sunlight. J Dermatol. 1996;23: 559-63.
39. Aghassi D, Dover JS. Pemphigus foliaceus induced by psoralen-UV-A. Arch Dermatol. 1998;134:1300-1.
40. Hymes SR, Jordon RE. Pemphigus foliaceus. Use of antimalarial agents as adjuvant therapy. Arch Dermatol. 1992; 128:1462-4.
41. Cram DL, Fukuyama K. Immunohistochemistry of ultraviolet-induced pemphigus and pemphigoid lesions. Arch Dermatol. 1972;106:819-24.
42. Kano Y, Shimosegawa M, Mizukawa Y, Shiohara T. Pemphigus foliaceus induced by exposure to sunlight. Report of a case and analysis of photochallenge-induced lesions. Dermatology. 2000;201:132-8.
43. Vozza A, Ruocco V, Brenner S, Wolf R. Contact pemphigus. Int J Dermatol. 1996;35:199-201.
44. Gallo R, Massone C, Parodi A, Guarrera M. Allergic contact dermatitis from thiurams with pemphigus-like autoantibodies. Contact Dermatitis. 2002;46:364-5.
45. Lin R, Ladd DJ Jr, Powell DJ, Way BV. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140:889-90.
46. Goldberg I, Sasson O, Brenner S. A case of phenol-related contact pemphigus. Dermatology. 2001;203:355-6.
47. Krauze E, Wygledowska-Kania M, Kaminska-Budzinska G, Lis A, Brzezinska-Wcislo L. Radiotherapy induced pemphigus vulgaris. Ann Dermatol Venereol. 2003;130:549-50.
48. Delaporte E, Piette F, Bergoend H. Pemphigus vulgaris induced by radiotherapy. Ann Dermatol Venereol. 1991; 118:447-51.
49. Low GJ, Keeling JH. Ionizing radiation-induced pemphigus. Case presentations and literature review. Arch Dermatol. 1990;126:1319-23.
50. Cerottini JP, Burren R, Panizzon RG. Pemphigus vulgaris occurring simultaneously on a recent and an old surgical scar due to a Koebner's phenomenon. Eur J Dermatol. 2000;10:546-7.
51. Reichert-Penetrat S, Barbaud A, Martin S, Omhover L, Weber M, Schmutz JL. Pemphigus vulgaris on an old surgical scar: Koebner's phenomenon? Eur J Dermatol. 1998;8:60-2.
52. Hasson A, Requena L, Arias D, Martin L, De Castro A. Linear pemphigus vulgaris along a surgical scar. Dermatologica. 1991;182:191-2.
53. Hogan P. Pemphigus vulgaris following a cutaneous thermal burn. Int J Dermatol. 1992;31:46-9.
54. Tur E, Brenner S. Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch Dermatol. 1998;134:1406-10.
55. Brenner S, Sasson A, Sharon O. Pemphigus and infections. Clin Dermatol. 2002;20:114-8.
56. Tufano MA, Baroni A, Buommino E, et al. Detection of herpesvirus DNA in peripheral blood mononuclear cells and skin lesions of patients with pemphigus by polymerase chain reaction. Br J Dermatol. 1999;141:1033-9.
57. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol. 2002;118: 845-50.
58. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354:667-72.
59. Anhalt GJ, Díaz LA. Prospects for autoimmune disease: Research advances in pemphigus. JAMA. 2001;285:652-4.
60. Martel P, Joly P. Pemphigus: autoimmune diseases of keratinocyte's adhesion molecules. Clin Dermatol. 2001;19: 662-74.
61. Devries DT, Warren SJ. Recent advances in intraepidermal blistering diseases. Adv Dermatol. 2002;18:203-45.
62. Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res. 2003;295 Suppl 1:2-11.
63. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869-77.
64. Buxton RS, Cowin P, Franke WW, et al. Nomenclature of the desmosomal cadherins. J Cell Biol. 1993;121:481-3.
65. Whittock NV. Genomic sequence analysis of the mouse desmoglein cluster reveals evidence for six distinct genes: characterization of mouse DSG4, DSG5, and DSG6. J Invest Dermatol. 2003;120:970-80.
66. Eyre RW, Stanley JR. Human autoantibodies against a desmosomal protein complex with a calcium-sensitive epitope are characteristic of pemphigus foliaceus patients. J Exp Med. 1987;165:1719-24.
67. Eyre RW, Stanley JR. Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. J Clin Invest. 1988;81:807-12.
68. Korman NJ, Eyre RW, Klaus-Kovtun V, Stanley JR. Demonstration of an adhering junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and pemphigus vulgaris. N Engl J Med. 1989;7,321:631-5.
69. Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol. 2001;1,167:5439-48.
70. Futei Y, Amagai M, Sekiguchi M, Nishifuji K, Fujii Y, Nishikawa T. Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris. J Invest Dermatol. 2000;115:829-34.
71. Stanley JR, Nishikawa T, Díaz LA, Amagai M. Pemphigus: is there another half of the story? J Invest Dermatol. 2001; 116:489-90.
72. Grando SA, Pittelkow MR, Shultz LD, Dmochowski M, Nguyen VT. Pemphigus: an unfolding story. J Invest Dermatol. 2001;117:990-5.
73. Udey MC, Stanley JR. Pemphigus-diseases of antidesmosomal autoimmunity. JAMA. 1999;282:572-6.
74. Stanley JR. The pathophysiology of pemphigus. J Dermatol Sci. 2000;24:155-7.
75. Koch PJ, Mahoney MG, Ishikawa H, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol. 1997;137:1091-102.
76. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest. 1994;94:59-67.
77. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol. 1995;104:895-901.
78. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147:261-5.
79. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest. 2000;105:625-31.
80. Beutner EH, Jordon RE. Demostration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964;117: 505-10.
81. Beutner EH, Lever WF, Witebsky E, Jordon R, Chertock B. Autoantibodies in pemphigus vulgaris: Response to an intercelular substance in epidermis. JAMA. 1965;92:682-8.
82. Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titers in pemphigus. Arch Dermatol. 1980;116:285-90.
83. Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol. 1988;124:1702-4.
84. Hup JM, Bruinsma RA, Boersma ER, De Jong MC. Neonatal pemphigus vulgaris: transplacental transmission of antibodies. Pediatr Dermatol. 1986;3:468-72.
85. Storer JS, Galen WK, Nesbitt LT Jr, DeLeo VA. Neonatal pemphigus vulgaris. J Am Acad Dermatol. 1982;6:929-32.
86. Michel B, Ko CS. An organ culture model for the study of pemphigus acantholysis. Br J Dermatol. 1977;96:295-302.
87. Schiltz JR. Pemphigus acantholysis: a unique immunological injury. J Invest Dermatol. 1980;74:359-62.
88. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Díaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982; 306:1189-96.
89. Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol. 2000;143:337-42.
90. Hacker MK, Janson M, Fairley JA, Lin MS. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol. 2002;105:64-74.
91. Spaeth S, Riechers R, Borradori L, Zillikens D, Budinger L, Hertl M. IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. Br J Dermatol. 2001;144:1183-8.
92. Jones CC, Hamilton RG, Jordon RE. Subclass distribution of human IgG autoantibodies in pemphigus. J Clin Immunol. 1988;8:43-9.
93. 4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci. 2001; 26:55-61.
94. Arteaga LA, Prisayanh PS, Warren SJ, Liu Z, Díaz LA, Lin MS; Cooperative Group on Fogo Selvagem Research. A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. J Invest Dermatol. 2002;118:806-11.
95. Kowalczyk AP, Anderson JE, Borgwardt JE, Hashimoto T, Stanley JR, Green KJ. Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1. J Invest Dermatol. 1995;105:147-52.
96. 1 autoantibodies. J Invest Dermatol. 2003;121: 1373-8.
97. Li N, Aoki V, Hans-Filho G, Rivitti EA, Díaz LA. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med. 2003;197:1501-10.
98. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol. 2000;114:88-94.
99. Tsunoda K, Ota T, Suzuki H, et al. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol. 2002;32:627-33.
100. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol. 2003;170:635-42.
101. Hacker-Foegen MK, Fairley JA, Lin MS. T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris. J Invest Dermatol. 2003; 121:1365-72.
102. Bhol KC, Rojas AI, Khan IU, Ahmed AR. Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid. Cytokine. 2000;12: 1076-83.
103. D'Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997;8:383-7.
104. Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev. 2003;2:278-83.
105. Patel HP, Díaz LA, Anhalt GJ, Labib RS, Takahashi Y. Demonstration of pemphigus antibodies on the cell surface of murine epidermal cell monolayers and their internalization. J Invest Dermatol. 1984;83:409-15.
106. Díaz LA, Marcelo CL. Pemphigoid and pemphigus antigens in cultured epidermal cells. Br J Dermatol. 1978;98:631-7.
107. Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol. 2001;1,167:5439-48.
108. Shimizu A, Ishiko A, Ota T, Tsunoda K, Amagai M, Nishikawa T. IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model. J Invest Dermatol. 2004;122:1145-53.
109. Mascaro JM Jr, España A, Liu Z, et al. Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence. Clin Immunol Immunopathol. 1997;85:90-6.
110. España A, Díaz LA, Mascaró JM Jr, et al. Mechanisms of acantholysis in pemphigus foliaceus. Clin Immunol Immunopathol. 1997;85:83-9.
111. Mahoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J Invest Dermatol. 1999;113:22-5.
112. Kitajima Y. Mechanisms of desmosome assembly and disassembly. Clin Exp Dermatol. 2002;27:684-90.
113. Sánchez-Carpintero I, España A, Pelacho B, et al. In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol. 2004;151:565-70.
114. Caldelari R, De Bruin A, Baumann D, et al. A central role for the armadillo protein plakoglobin in the autoimmune disease pemphigus vulgaris. J Cell Biol. 2001;153:823-34.
115. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11:429-52.
116. Martel P, Joly P. Pemphigus. Encycl Méd Chir (Editions Scientifiques et Médicales Elsevier SAS, Paris) Dermatologie. 2000;98-250-A-10.
117. España A, Sánchez-Carpintero I, Díaz LA. Pénfigo vulgar. En: España A, Mascaró JM, editores. Enfermedades ampollosas. Madrid: Grupo Aula Médica; 2004. p. 105-28.
118. Stanley JR. Pemphigus. En: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 2003. p. 558-67.
119. Ahmed AR, Sami N. Uncommon manifestations of pemphigus vulgaris. JEADV. 2002;16:313-5.
120. Schlesinger N, Katz M, Ingber A. Nail involvement in pemphigus vulgaris. Br J Dermatol. 2002;146:836-9.
121. Ahmed AR, Blose DA. Pemphigus vegetans. Neumann type and Hallopeau type. Int J Dermatol. 1984;23:135-41.
122. Kawana S, Hashimoto T, Nishikawa T, Nishiyama S. Changes in clinical features, histologic findings, and antigen profiles with development of pemphigus foliaceus from pemphigus vulgaris. Arch Dermatol. 1994;130:1534-8.
123. Chang SN, Kim SC, Lee IJ, Seo SJ, Hong CK, Park WH. Transition from pemphigus vulgaris to pemphigus foliaceus. Br J Dermatol. 1997;137:303-5.
124. Komai A, Amagai M, Ishii K, et al. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. Br J Dermatol. 2001;144:1177-82.
125. Harman KE, Gratian MJ, Shirlaw PJ, Bhogal BS, Challacombe SJ, Black MM. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris. Br J Dermatol. 2002;146:684-7.
126. Patten SF, Dijkstra JW. Associations of pemphigus and autoimmune disease with malignancy or thymoma. Int J Dermatol. 1994;33:836-42.
127. España A, Díaz LA. Pénfigo foliáceo. En: España A, Mascaró JM, editores. Enfermedades ampollosas. Madrid: Grupo Aula Médica; 2004. p. 85-104.
128. Megahed M. Histopathology of blistering diseases with clinical, electron microscopic, immunological and molecular biologic correlations. Berlin: Springer-Verlag; 2004. p. 49-118.
129. David M, Weissman-Katzenelson V, Ben-Chetrit A, Hazaz B, Ingber A, Sandbank M. The usefulness of immunofluorescent tests in pemphigus patients in clinical remission. Br J Dermatol. 1989;120:391-5.
130. Ratnam KV, Pang BK. Pemphigus in remission: value of negative direct immunofluorescence in management. J Am Acad Dermatol. 1994;30:547-50.
131. Karlhofer FM, Hashimoto T, Slupetzky K, et al. 230-kDa and 190-kDa proteins in addition to desmoglein 1 as immunological targets in a subset of pemphigus foliaceus with a combined cell-surface and basement membrane zone immune staining pattern. Exp Dermatol. 2003;12:646-54.
132. Sabolinski ML, Beutner EH, Krasny S, et al. Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus sections. J Invest Dermatol. 1987;88:545-9.
133. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A. 1995;92:5239-43.
134. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159:2010-7.
135. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998;102:775-82.
136. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999;40(2 Pt 1):167-70.
137. Ding X, Aoki V, Mascaró JM Jr, López-Swiderski A, Díaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol. 1997;109:592-6.
138. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol. 2000;142:1135-9.
139. Bystryn JC, Akman A, Jiao D. Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus. Arch Dermatol. 2002; 138:1252-3.
140. Ding X, Díaz LA, Fairley JA, Giudice GJ, Liu Z. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol. 1999;112:739-43.
141. Ljubojevic S, Lipozencic J, Brenner S, Budimcic D. Pemphigus vulgaris: a review of treatment over a 19-year period. JEADV. 2002;16:599-603.
142. Stanley JR. Therapy of pemphigus vulgaris. Arch Dermatol. 1999;135:76-8.
143. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003; 149:926-37.
144. Mimouni D, Anhalt GJ. Pemphigus. Dermatol Ther. 2002; 15:362-8.
145. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422-7.
146. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132:203-12.
147. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34:645-52.
148. Fellner MJ, Sapadin AN. Current therapy of pemphigus vulgaris. Mt Sinai J Med. 2001;68:268-78.
149. Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol. 2001;137: 477-81.
150. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49:1059-62.
151. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113:1236-41.
152. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol. 1984;120:44-7.
153. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol. 1984;120:941-51.
154. Bystryn JC. Therapy of pemphigus. Semin Dermatol. 1988; 7:186-94.
155. Bystryn JC. How should pemphigus be treated? JEADV. 2002;16:562-3.
156. Sabir S, Werth VP. Pulse glucocorticoids. Dermatol Clin. 2000;18:437-46.
157. Toth GG, Van de Meer JB, Jonkman MF. Dexamethasone pulse therapy in pemphigus. JEADV. 2002;16:607-11.
158. Perry HO, Brunsting LA. Pemphigus foliaceus. Arch Dermatol. 1965;91:10-23.
159. Dumas V, Roujeau JC, Wolkenstein P, Revuz J, Cosnes A. The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid. Br J Dermatol. 1999;140:1127-9.
160. Huilgol SC, Black MM. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol. 1995; 20:283-93.
161. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058-64.
162. Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol. 1988; 124:1659-63.
163. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22:35-40.
164. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058-64.
165. Luftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol. 2003;149: 598-605.
166. Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol. 2001;45:775-83.
167. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol. 2001;26:127-31.
168. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002; 47:358-63.
169. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:679-90.
170. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol. 2002;46:42-9.
171. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol. 1987;16:527-33.
172. Gupta MT, Jerajani HR. Control of childhood pemphigus erythematosus with steroids and azathioprine. Br J Dermatol. 2004;150:163-4.
173. Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol. 1999;135:57-61.
174. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003;49:276-80.
175. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol. 1988;119:73-7.
176. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990;29:371-4.
177. Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone- cyclophosphamide pulse therapy in pemphigus. Dermatology. 2002;204:228-31.
178. Jain R, Kumar B. Immediate and delayed complications of dexamethasone cyclophosphamide pulse (DCP) therapy. J Dermatol. 2003;30:713-8.
179. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol. 2000; 43:1065-9.
180. Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol. 2003;49:148-50.
181. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138-45.
182. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139:739-42.
183. Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol. 1999;135:853-4.
184. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol. 2000;136:868-72.
185. Vardy DA, Cohen AD. Cyclosporine therapy should be considered for maintenance of remission in patients with pemphigus. Arch Dermatol. 2001;137:505-6.
186. Shah N, Green AR, Elgart GW, Kerdel F. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol. 2000;42:85-8.
187. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135: 1275-6.
188. Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol. 1998;134:1104-7.
189. Chen S, Lu X, Zhou G. Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline. Int J Dermatol. 2003;42:981-2.
190. Calebotta A, Saenz AM, González F, Carvalho M, Castillo R. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol. 1999;38:217-21.
191. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148:602-3.
192. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol. 2003;28:366-8.
193. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140:91-6.
194. Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149: 899-901.
195. España A, Fernández-Galar M, Lloret P, Sánchez- Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50:974-6.
196. Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9:136-41.
197. Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol. 2002;147:725-32.
198. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol.
199. Caneppele-Carel S, Mazereeuw-Hautier J, Bazex J. Actualités du pemphigus paranéoplasique. Ann Dermatol Venereol. 2001;128:561-6.
200. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004;9:29-33.
201. Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. Australas J Dermatol. 2005;46:1-8; quiz 9-10.
202. Herrero González JE, Iranzo Fernández P, Mascaró Galy JM. Pénfigo paraneoplásico. En: España A, Mascaró JM, editores. Enfermedades ampollosas. Madrid: Grupo Aula Médica; 2004. p. 129-40.
203. Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193-206.
204. Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Am Acad Dermatol. 2001;44:593-8.
205. Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol. 1992;128:1091-5.
206. Mehregan DR, Oursler JR, Leiferman KM, Muller SA, Anhalt GJ, Peters MS. Paraneoplastic pemphigus: a subset of patients with pemphigus and neoplasia. J Cutan Pathol. 1993;20:203-10.
207. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 1995;32:441-7.
208. Hashimoto T. Immunopathology of paraneoplastic pemphigus. Clin Dermatol. 2001;19:675-82.
209. Futei Y, Amagai M, Hashimoto T, Nishikawa T. Conformational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J Am Acad Dermatol. 2003;49:1023-8.
210. Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol. 1995;132:474-8.
211. Nousari HC, Kimyai-Asadi A, Anhalt GJ. Elevated levels of interleukin-6 in paraneoplastic pemphigus. J Invest Dermatol. 1999;112:396-8.
212. Wang L, Bu D, Yang Y, Chen X, Zhu X. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363:525-31.
213. Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619-26.
214. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142-4.
215. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;6,340:1406-10.
216. Maciejowska E, Jablonska S, Chorzelski T. Is pemphigus herpetiformis an entity? Int J Dermatol. 1987;26:571-7.
217. Santi CG, Maruta CW, Aoki V, Sotto MN, Rivitti EA, Díaz LA. Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. Cooperative Group on Fogo Selvagem Research. J Am Acad Dermatol. 1996;34:40-6.
218. Kubota Y, Yoshino Y, Mizoguchi M. A case of herpetiform pemphigus associated with lung cancer. J Dermatol. 1994; 21:609-11.
219. Palleschi GM, Giomi B. Herpetiformis pemphigus and lung carcinoma: a case of paraneoplastic pemphigus. Acta Derm Venereol. 2002;82:304-5.
220. Marinovic B, Basta-Juzbasic A, Bukvic-Mokos Z, Leovic R, Loncaric D. Coexistence of pemphigus herpetiformis and systemic lupus erythematosus. J Eur Acad Dermatol Venereol. 2003;17:316-9.
221. Morita E, Amagai M, Tanaka T, Horiuchi K, Yamamoto S. A case of herpetiform pemphigus coexisting with psoriasis vulgaris. Br J Dermatol. 1999;141:754-5.
222. Sánchez-Palacios C, Chan LS. Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol. 2004;31:346-9.
223. Kozlowska A, Hashimoto T, Jarzabek-Chorzelska M, et al. Pemphigus herpetiformis with IgA and IgG antibodies to desmoglein 1 and IgG antibodies to desmocollin 3. J Am Acad Dermatol. 2003;48:117-22.
224. Kubo A, Amagai M, Hashimoto T, et al. Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (desmoglein 3). Br J Dermatol. 1997;137:109-13.
225. Shimizu K, Hashimoto T, Wang N, et al. A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Dermatology. 1996;192:179-82.
226. O'Toole EA, Mak LL, Guitart J, et al. Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a pemphigus variant. Clin Exp Immunol. 2000;119:217-24.
227. Beutner EH, Chorzelski TP, Wilson RM, et al. IgA pemphigus foliaceus. Report of two cases and a review of the literature. J Am Acad Dermatol. 1989;20:89-97.
228. Huff JC, Golitz LE, Kunke KS. Intraepidermal neutrophilic IgA dermatosis. N Engl J Med. 1985;26,313:1643-5.
229. Teraki Y, Amagai N, Hashimoto T, Kusunoki T, Nishikawa T. Intercellular IgA dermatosis of childhood. Selective deposition of monomer IgA1 in the intercellular space of the epidermis. Arch Dermatol. 1991;127:221-4.
230. Yasuda H, Kobayashi H, Hashimoto T, Itoh K, Yamane M, Nakamura J. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol. 2000;143: 144-8.
231. Tagami H, Iwatsuki K, Iwase Y, Yamada M. Subcorneal pustular dermatosis with vesiculo-bullous eruption. Demonstration of subcorneal IgA deposits and a leukocyte chemotactic factor. Br J Dermatol. 1983;109:581-7.
232. Hashimoto T, Inamoto N, Nakamura K, Nishikawa T. Intercellular IgA dermatosis with clinical features of subcorneal pustular dermatosis. Arch Dermatol. 1987;123: 1062-5.
233. Hashimoto T. Immunopathology of IgA pemphigus. Clin Dermatol. 2001;19:683-9.
234. Maciejowska E, Jablonska S, Chorzelski T. Is pemphigus herpetiformis an entity? Int J Dermatol. 1987;26:571-7.
235. Hashimoto T, Kiyokawa C, Mori O, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol. 1997;109:127-31.
236. Wang J, Kwon J, Ding X, Fairley JA, Woodley DT, Chan LS. Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol. 1997;150:1901-7.
237. Ebihara T, Hashimoto T, Iwatsuki K, et al. Autoantigens for IgA anti-intercellular antibodies of intercellular IgA vesiculopustular dermatosis. J Invest Dermatol. 1991;97:742-5.
238. Hisamatsu Y, Amagai M, Garrod DR, Kanzaki T, Hashimoto T. The detection of IgG and IgA autoantibodies to desmocollins 1-3 by enzyme-linked immunosorbent assays using baculovirus-expressed proteins, in atypical pemphigus but not in typical pemphigus. Br J Dermatol. 2004; 151:73-83.
239. Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol. 2004;1:62-6.
240. Ruiz-Genao DP, Hernández-Núñez A, Hashimoto T, Amagai M, Fernández-Herrera J, García-Díez A. A case of IgA pemphigus successfully treated with acitretin. Br J Dermatol. 2002;147:1040-2.
241. Hodak E, Lapidoth M, David M. Effect of colchicine in the subcorneal pustular dermatosis type of IgA pemphigus. J Am Acad Dermatol. 1999;40:91-4.